New drug AMN1126 passes first safety check in healthy women
Knowledge-focused
Completed
This early-stage study tested a single dose of the experimental drug AMN1126 in 18 healthy postmenopausal women to see if it is safe and how the body processes it. The goal was not to treat any disease, but to gather initial safety information and measure drug levels in the blood…
Phase: PHASE1 • Sponsor: Amneal Pharmaceuticals, LLC • Aim: Knowledge-focused
Last updated May 26, 2026 12:06 UTC